Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics outlines Q4 2026 immunology and oncology data milestones

Neutral Impact 2 of 5 product/contract Written later

Cullinan Therapeutics said it plans to share clinical data for three T cell engager programs in the fourth quarter of 2026, including velinotamig data at the ACR Convergence 2026 meeting in November and CLN-978 and CLN-049 updates in December. The filing is a pipeline timing update with no financial results, guidance, or financial figures, so it does not change the company's reported financial position.

Key points

  • Velinotamig multi-dose data in SLE to be presented in a poster session at ACR Convergence 2026 on November 8, 2026
  • CLN-978 multi-dose and single target dose data in SLE, RA, and Sjögren's disease planned for December
  • CLN-049 updated dose escalation data in relapsed/refractory AML planned for December, following a meeting with the FDA that the CEO called successful

The filing

CompanyCullinan Therapeutics, Inc. (CGEM)
Form8-K, current report
Filed with the SECSep 24, 2026, 7:15 AM ET
Accession number0001193125-26-400144

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.